A chronic, relapsing, inflammatory skin condition, atopic dermatitis (AD) is associated with a high disease burden that affects patients’ quality of life. AD involving the head and neck and/or genital regions is particularly associated with social embarrassment and stigmatisation, with a corresponding negative effect on patients’ mental health.
Tralokinumab, an IL-13 inhibitor, is an approved biologic therapy for patients with moderate-to-severe AD. New data reported at key dermatology congresses in the latter half of 2024 are summarised in this review, including results from a matching-adjusted indirect comparison (MAIC) and long-term trial and real-world findings.
